DrawDose publishes technical reference material on peptide reconstitution math, dosing protocols sourced from public regulatory documentation, and procedural information for handling lyophilized research peptides. This page documents how that material is sourced, reviewed, and updated.
DrawDose is operated by Agensum LLC, an Illinois limited liability company.
The position throughout: DrawDose is editorial, not clinical. No physicians, pharmacists, or other licensed healthcare professionals are on staff. Content is researched against primary sources and published as a reference for users who already have access to the substances and procedures described. We do not provide medical advice, prescribe, recommend treatment, or direct content at patients seeking care.
What DrawDose publishes
Three categories of content live on this site. Calculation tools that perform reconstitution math (BAC water volume, syringe units, concentration) for any combination of peptide amount, water volume, and dose. Reference pages that document publicly available information about specific peptides — molecular structure, FDA-approved manufacturer dosing schedules, half-life, common reconstitution ratios, side effect profiles per prescribing information, and community-reported protocol variations. Procedural guides that describe the mechanical steps of reconstituting lyophilized peptide powder with bacteriostatic water.
We do not publish recommendations on whether to use a specific peptide, advice on whether a peptide is right for a given person, claims about therapeutic outcomes beyond what manufacturer prescribing information states, or any content directed at patients in a treatment relationship.
How content is sourced
Every dosing schedule, side effect profile, half-life value, and pharmacological description on this site traces to one of four source categories. Each peptide page lists its sources in the footer and in the structured data citation array.
Primary regulatory documents. FDA-approved drug prescribing information for any peptide that has been approved for any indication. This includes Mounjaro and Zepbound prescribing information for tirzepatide content, Ozempic and Wegovy prescribing information for semaglutide content, Egrifta prescribing information for tesamorelin content, and so on. Where a peptide has no FDA approval, this category does not apply.
Peer-reviewed scientific literature. PubMed-indexed papers on peptide chemistry, pharmacokinetics, and clinical trial outcomes. Research peptides without FDA approval (BPC-157, TB-500, GHK-Cu, and similar) draw their pharmacological descriptions from this category, with explicit acknowledgement that the literature is preclinical or limited human trial work, not regulatory-grade evidence.
Manufacturer documentation. Compounding pharmacy formulation specifications, vial labels, and Certificates of Analysis for batches in active circulation. Used for content describing how compounded peptides differ from FDA-approved branded equivalents in concentration, vial size, and storage requirements.
Community protocol surveys. Aggregated user-reported dosing patterns from r/Peptides, r/Tirzepatide, r/CompoundedTirzepatide, r/Semaglutide, r/Retatrutide, and similar communities. Used only for content describing variations from manufacturer protocols (slow titration, microdosing, off-label patterns) and explicitly labeled as community-reported with sample size context where available. Community data is never the source for safety information, dosing minimums, or contraindication warnings.
When sources conflict, manufacturer prescribing information takes precedence over peer-reviewed literature, which takes precedence over community surveys. Conflicts are noted explicitly on the page rather than resolved silently.
Review and update cadence
Every reference page carries a lastReviewed date in its frontmatter, visible in the page footer and emitted in structured data. This date reflects the most recent review of the content against current primary sources, not the file modification date.
Pages are reviewed at least every 12 months. Pages covering peptides with active FDA labeling changes, manufacturer recalls, or significant new clinical trial data are reviewed and updated within 30 days of the new information becoming public. Pages older than 12 months without review are flagged in our internal queue and prioritized.
Content changes from review fall into three categories: factual corrections (math errors, transcription errors, source citations updated), substantive updates (new dosing schedule from updated prescribing information, new safety information, new community protocol consensus), and editorial changes (clarity, structure, register). All three trigger a dateModified update; only factual and substantive updates trigger lastReviewed.
Editorial team
DrawDose content is researched, written, and reviewed by a small editorial team. No member of the editorial team holds a medical license, pharmacy license, or other healthcare professional credential. We are publishers and researchers, not clinicians.
Content is reviewed against primary sources rather than peer-reviewed by physicians. Where content describes pharmacological effects, dosing schedules, or side effects, the source is a manufacturer prescribing information document or peer-reviewed paper, not a clinician's interpretation. Readers seeking clinical interpretation, individualized dosing decisions, or treatment recommendations should consult a licensed healthcare provider in their jurisdiction.
This is intentional. Pretending to clinical authority we do not have would be dishonest and would also expose readers to the worse failure mode of trusting unqualified medical opinions. Our editorial value is sourcing rigor, math accuracy, and transparency about what we are.
Conflict of interest and affiliate relationships
DrawDose generates revenue from three sources: optional paid features in the iOS and Android applications, affiliate commissions from peptide vendor recommendations on the /vendors comparison page, and direct support from users who choose to contribute. The reference content (calculator, peptide pages, guides) is free and not gated by any of these.
DrawDose participates in affiliate programs with selected peptide vendors. When a reader follows a link from this site to a vendor and makes a purchase, DrawDose may earn a commission, paid by the vendor at no additional cost to the reader. Affiliate relationships are disclosed on the /vendors page with the commission structure stated explicitly, and on any peptide page that mentions a specific vendor.
Affiliate relationships do not influence editorial coverage, ranking, or content depth. Vendors that pay higher commission rates are not ranked higher than vendors that pay less. Vendors cannot purchase editorial placement, content modification, or ranking position. Selection and ranking criteria for the /vendors page are documented on that page.
DrawDose does not accept payment, free product, or other consideration from peptide manufacturers, compounding pharmacies, or pharmaceutical companies. We have no affiliation with Eli Lilly, Novo Nordisk, or any other manufacturer of any peptide referenced on the site.
Correction policy
Errors happen. When a reader identifies a factual error in published content — math errors in the calculator, incorrect dosing information, miscited sources, outdated regulatory information — we correct the error within five business days of verification.
Corrections to substantive errors (dosing, safety, regulatory status) include a visible correction note at the top of the affected page for 30 days following the correction, stating what was incorrect and what it was changed to. Minor corrections (typos, broken links, formatting) are made silently.
The correction queue is processed weekly. Submissions are acknowledged within two business days; resolution timelines depend on the complexity of the verification required.
Contact
Email: hello@agensum.com
For correction submissions, include the page URL, the specific text or value in question, and the source you believe is correct. We acknowledge every submission and respond with our verification within five business days.
For sourcing questions about specific claims, we will provide the primary source citation for any factual claim on the site. Where content is sourced from community surveys or aggregated user reports, we will provide the methodology and sample size context where available.
For media, partnership, and legal inquiries, use the same address.